More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
AUM
$516361647
P/E ratio
15
Dividend yield
0.7841%
Expense ratio
0.35%
Beta
0.625238
Previous close
$66.83
Today's open
$66.85
Day's range
$65.21 - $67.14
52 week range
$50.95 - $74.35
Industries
Health
INDV:MB
Indivior Pharmaceuticals Inc
3.74%
2.75%
MANE
Veradermics Inc
2.71%
2.64%
2.61%
2.47%
2.36%
VTRS
Viatris Inc
2.36%
PFE
Pfizer Inc
2.3%
2.29%
Which Healthcare ETF Is Best for the Long Term: State Street's XPH or Invesco's PBE?
State Street SPDR S&P Pharmaceuticals ETF provides a more diversified and lower-cost entry to the healthcare sector than its Invesco counterpart. Invesco Biotechnology & Genome ETF focuses on a narrower set of biotechnology stocks and offers a significantly higher dividend yield.
The Motley Fool • Nov 15, 2026

Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street's XPH or First Trust's FBT?
State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund. First Trust NYSE Arca Biotechnology Index Fund has delivered higher total returns over the past one-year and five-year periods.
The Motley Fool • Nov 11, 2026

How to Invest in the Rise of China's Biotech: Buy U.S. Drug Stocks
Many of the hot new drug candidates in the U.S. were developed Chinese companies.
Barrons • Nov 3, 2026

Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF
VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with more than twice as many individual holdings.
The Motley Fool • Oct 30, 2026

Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK?
State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio but has a lower dividend yield than Simplify Health Care ETF. Simplify Health Care ETF has shown significantly lower maximum drawdowns than the SPDR fund over the last five years.
The Motley Fool • Oct 26, 2026

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Zacks Investment Research • Oct 21, 2026

XPH: Healthcare Sector Dashboard For October
Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharma exposure with low company-specific risk due to its modified equal-weight methodology. XPH is best suited for tactical allocation or swing trading, not as a compelling long-term holding, given its historical risk-return profile and sector dynamics.
Seeking Alpha • Oct 16, 2026

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
The VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%. The State Street SPDR S&P Pharmaceuticals ETF is more diversified with 62 holdings, while the VanEck Biotech ETF focuses on 25 holdings.
The Motley Fool • Oct 10, 2026

Better Pharma ETF: iShares IHE vs. State Street XPH
The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.
The Motley Fool • Oct 10, 2026

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on June 19, 2006.
Zacks Investment Research • Oct 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell SPDR S&P Pharmaceuticals ETF commission-free¹. Build wealth for the long term using automated trading and transfers.